NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
Reading WST? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track WST free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Supplies: fringe margins under pressure (1q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 11% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 35% growth a year, above the roughly 7% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskWST's growth in injectable drugs supports its revenue potential. The company recently beat earnings expectations by 27%, with revenue growing 21% year over year. It trades at 45× P/E, above the peer median of 30×. The market seems to expect more growth than is justified. If WST cuts guidance, it could face a significant decline. Peer multiples imply a price about 36% below where it trades. This read is provisional.
Trailing returns as of 2026-07-07. WST is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering WST (as of Jul 2026).
Based on 4 Wall Street analysts offering 12-month price targets for WST in the last 4 months.
A consensus fair price across 13 valuation methods, at three horizons. Current price $356.08. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Supplies — fair value, gap to price, and forward P/E.
Advances: Increase full-year 2026 revenue guidance
Upgrade indicates strong growth potential for 2026 revenue.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $356.08
The last 12 months of price, then the range of analyst 12-month targets from today’s $356.08.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase full-year 2026 revenue guidance
Injectable drug growth supports revenue objectives.
Advances: Increase full-year 2026 EPS guidance
Exceeding earnings estimates supports EPS growth.
